Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aztreonam-avibactam vs best available therapy in children with serious Gram-negative infections
CTR20233317Phase 2Active
- Sponsor
- Pfizer
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of aztreonam + avibactam in Gram-negative bacterial infection, Intra-abdominal infection (IAI), complicated urinary tract infection (cUTI), hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), sponsored by Pfizer. Started Jul 2024; status: active.
02
Drugs
aztreonam + avibactam
03
Conditions
Gram-negative bacterial infectionIntra-abdominal infection (IAI)complicated urinary tract infection (cUTI)hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on CTR20233317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233317.